178 related articles for article (PubMed ID: 36063655)
1. Genetic alterations shaping tumor response to anti-EGFR therapies.
Vaquero J; Pavy A; Gonzalez-Sanchez E; Meredith M; Arbelaiz A; Fouassier L
Drug Resist Updat; 2022 Sep; 64():100863. PubMed ID: 36063655
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.
Leonetti A; Assaraf YG; Veltsista PD; El Hassouni B; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Jan; 42():1-11. PubMed ID: 30544036
[TBL] [Abstract][Full Text] [Related]
4. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
[TBL] [Abstract][Full Text] [Related]
5. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y; Wang H; He C
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
9. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
10. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
Linardou H; Dahabreh IJ; Kanaloupiti D; Siannis F; Bafaloukos D; Kosmidis P; Papadimitriou CA; Murray S
Lancet Oncol; 2008 Oct; 9(10):962-72. PubMed ID: 18804418
[TBL] [Abstract][Full Text] [Related]
11. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
12. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
13. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
[TBL] [Abstract][Full Text] [Related]
14. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
Knebel FH; Bettoni F; Shimada AK; Cruz M; Alessi JV; Negrão MV; Reis LFL; Katz A; Camargo AA
Lung Cancer; 2017 Jun; 108():238-241. PubMed ID: 28625643
[TBL] [Abstract][Full Text] [Related]
15. Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
Shah MP; Neal JW
Drugs; 2022 Apr; 82(6):649-662. PubMed ID: 35412115
[TBL] [Abstract][Full Text] [Related]
16. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
17. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.
Dong RF; Zhu ML; Liu MM; Xu YT; Yuan LL; Bian J; Xia YZ; Kong LY
Pharmacol Res; 2021 May; 167():105583. PubMed ID: 33775864
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.
De Luca A; Normanno N
Curr Drug Targets; 2010 Jul; 11(7):851-64. PubMed ID: 20388064
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.
McCoach CE; Jimeno A
Drugs Today (Barc); 2016 Oct; 52(10):561-568. PubMed ID: 27910964
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.
Diao Z; Han Y; Zhang R; Li J
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188363. PubMed ID: 32275933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
